Amyotrophic Lateral Sclerosis (ALS) Treatment 2018-2026 Global Market by Key Players, Regions and Applications
Amyotrophic
lateral sclerosis (ALS), also known as Lou Gehrig's disease
and motor neuron disease (MND), is a neurodegenerative disease,
affecting nerve cells in the brain and spinal cord that controls
voluntary muscles. The disease is progressive in nature, meaning it
gets worse over time.
According to a study
published in Centers for Disease Control and Prevention, in 2016,
around 14,713 people were diagnosed with ALS in the U.S. and
prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The
prevalence rate increased to 5.0 cases per 100,000 people and around
15,908 people were diagnosed with ALS in 2013, according to the same
study. The increasing prevalence of ALS is in turn, expected to
support growth of the amyotrophic lateral sclerosis (ALS) treatment
market in the near future.
Approval of novel
innovative drugs is expected to boost growth in amyotrophic lateral
sclerosis treatment market
In May 2017, The
U.S. Food and Drug Administration (FDA) approved Radicava
(edaravone), an innovative drug used in the treatment of amyotrophic
lateral sclerosis (ALS). This was the first drug to be approved after
over 20 years since the last FDA-approved drug for ALS. The approval
of this drug would provide an additional option for patients
suffering from this deadly disease. Increasing incidence of ALS is
expected to increase the adoption rate of this drug, in turn,
boosting market growth. The drug has already been approved in Japan
and South Korea in 2015.
Initiatives taken by
some associations to increase awareness about diagnosis and treatment
of ALS among population is also expected to drive market growth
during forecast period (2017-2025). For instance in 2014, the ALS Ice
Bucket Challenge, a social media–centered campaign, received
extensive public visibility and created increased awareness of ALS.
In 2015, a group of ALS organizations in the U.S., including the ALS
Association, Les Turner ALS Foundation, and ALS Therapy Development
Institute, re-introduced the Ice Bucket Challenge to raise further
funds and spread awareness about ALS among population.
Global
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy
The global
amyotrophic lateral sclerosis treatment market is segmented on the
basis of drug type and distribution channel.
On the basis of drug
type, the global amyotrophic lateral sclerosis treatment market is
segmented into:
Riluzole
Edaravone
(Radicava)
On the basis of
distribution channel, the global amyotrophic lateral sclerosis
treatment market is segmented into:
Hospital
Pharmacies
Retail &
Online Pharmacies
Inquire Here
Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1206
North America is
expected to hold a dominant position in the market, increasing focus
of manufacturers on novel drug development for ALS
North America is
expected to hold a dominant position in the amyotrophic lateral
sclerosis treatment market, as major companies present in the region
are focusing on collaborations for product development. For instance,
in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc.
collaborated for the development of a potential gene therapy using
zinc finger protein transcription factors (ZFP-TFs) for the treatment
of ALS. Companies based in emerging economies of Asia Pacific are
focusing on developing novel drugs for treatment of ALS. For instant
major companies such as Mitsubishi Tanabe Pharma Corporation and
Takeda Pharmaceutical Company Ltd are developing drugs for treatment
of ALS.
Major players are
collaborating with various research institutes and companies for the
development of drug for amyotrophic lateral sclerosis treatment
In December 2017,
Mitsubishi Tanabe Pharma Corporation, Order made Medical Research
Corporation and Trans Chromosomics Inc. have completed strategic
collaboration for the development of antibody drug to treat
neurodegenerative diseases such as ALS. Takeda Pharmaceutical Company
Ltd. collaborated with Montreal Neurological Institute for the
discovery of new drugs for ALS in the same month. In 2016, Evotec and
Celgene Corporation have entered into a strategic drug discovery for
the development of new drugs for neurodegenerative diseases such as
ALS. In 2013 Janssen Research & Development, Division of Janssen
Pharmaceutica NV, and Johnson & Johnson collaborated, with three
prominent Belgian academic institutions and research centers for the
discovery of new treatment drugs for neurodegenerative diseases such
as ALS.
Major players
operating in the global amyotrophic lateral sclerosis treatment
market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical
Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment